Australia

Archived Projects: 19

Project Investigator All Locations Start date End date
VIPS: Vascular Effects of Infection in Pediatric Stroke Heather J. Fullerton, MD China, Malaysia, Argentina, Chile, Australia
DARE: Delaney AIDS Research Enterprise to Find a Cure Steven G. Deeks, MD Sweden, Australia
Adolescents with Eating Disorders Project - The Baker Foundation Collaboration with the University of Melbourne Daniel F. Le Grange, PhD Australia
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Ann V. Schwartz, PhD, MPH South Africa, India, Thailand, Belgium, Ireland, Italy, Spain, United Kingdom, Brazil, Peru, Australia
Multicenter Uveitis Steroid Treatment (MUST) Trial Nisha Acharya, MD United Kingdom, Australia
International Collaborative of prospective studies of HIV and Hepatitis in IDU Stephen Shiboski, PhD Australia
Office of the UN Special Envoy for Tuberculosis Eric Goosby, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Central Asia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, South Korea, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Caribbean, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, United States, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
AIDS Malignancies Consortium Lawrence D. Kaplan, MD Kenya, Uganda, Zimbabwe, South Africa, India, Brazil, Australia
International Collaborative of Prospective Studies of HIV and Hepatitis in IDU Kimberly A. Page, PhD, MPH Netherlands, Canada, Australia
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Anne F. Luetkemeyer, MD France, Germany, Italy, Russia, Spain, United Kingdom, Argentina, Puerto Rico, Canada, Australia
Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Michelle E. Melisko, MD France, Germany, Ireland, Spain, Switzerland, United Kingdom, Canada, Australia
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 Mandana Khalili, MD Egypt, Sweden, Mexico, Puerto Rico, Canada, Australia
Women, Children, and HIV Website Susan C. Coffey, MD Kenya, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Botswana, Lesotho, Namibia, South Africa, Swaziland, Gambia, Ghana, Liberia, Nigeria, India, Pakistan, Sri Lanka, Singapore, Philippines, United Kingdom, Anguilla, Antigua and Barbuda, Bahamas, Barbados, Cayman Islands, Dominica, Grenada, Jamaica, Saint Kitts and Nevis, Saint Lucia, Trinidad and Tobago, U.S. Virgin Islands, Northern Mariana Islands, Australia, Marshall Islands, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
Assess Clonidine and Aspirin in Noncardiac Surgery Patients at Risk of Perioperative Cardiovascular Event Rachel E. McKay, MD South Africa, China, India, Pakistan, Malaysia, Austria, Belgium, Denmark, France, Germany, Italy, Spain, Switzerland, United Kingdom, Argentina, Brazil, Chile, Colombia, Peru, Canada, Australia
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus Mandana Khalili, MD Mexico, Argentina, Puerto Rico, Australia
WHO Adolescent HTC Review Update (PO# 200660799) George W. Rutherford, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Western Africa, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, Japan, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka, Brunei, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
San Francisco National Clinical Trial Center, ESPIRIT Steven G. Deeks, MD Morocco, Japan, Singapore, Thailand, Israel, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, United Kingdom, Argentina, Brazil, Canada, Australia
International AIDS Education and Training Center E. Michael Reyes, MD, MPH Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Gabon, Egypt, Morocco, Sudan, Tunisia, Botswana, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Ivory Coast, Gambia, Ghana, Guinea-Bissau, Mali, Niger, Nigeria, Senegal, Togo, Kyrgyzstan, China, Bangladesh, India, Iran, Nepal, Pakistan, Sri Lanka, Cambodia, Indonesia, Viet Nam, Laos, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Georgia, Iraq, Lebanon, Yemen, Czech Republic, Estonia, Greece, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Venezuela, Antigua and Barbuda, Bahamas, Barbados, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Puerto Rico, Trinidad and Tobago, Australia
Failure Time Methods for Family Disease Studies David V. Glidden, PhD United States, Australia